Nafithromycin is a novel oral bacteriostatic antibiotic belonging to the fluoroketolide class, developed for the potential treatment of community-acquired bacterial pneumonia. By inhibiting the 50S subunit… Read more
Nafithromycin is a novel oral bacteriostatic antibiotic belonging to the fluoroketolide class, developed for the potential treatment of community-acquired bacterial pneumonia. By inhibiting the 50S subunit of the bacterial ribosome, this compound effectively prevents the protein synthesis required for microbial growth. This category provides essential reference standards, including pharmacopeial and non-pharmacopeial impurities, as well as stable isotope labelled compounds, which are critical for rigorous pharmaceutical analysis. Laboratory professionals rely on these high-quality materials for impurity profiling, method validation, and ongoing quality control of the active pharmaceutical ingredient. Utilizing these precise analytical tools ensures the accurate identification and quantification of impurities, supporting the stringent safety and regulatory requirements necessary during the development and manufacturing of new antibiotic therapies.